CVTX CV Therapeutics (MM)

CV Therapeutics, Inc. (“CV Therapeutics” or the “Company”) currently expects to record approximately $21 million of net product revenues from sales of Ranexa ^® (ranolazine extended-release tablets) for the quarter ended December 31, 2007. The Company currently estimates that its operating expenses, not including cost of sales, will be approximately $50 million to $55 million for the quarter ended December 31, 2007 and into 2008, which is consistent with the Company’s previously disclosed guidance. Product and collaboration revenues, which are not reflected in this operating expense figure, will offset a portion of operating expenses. The Company further estimates that it will report cash, cash equivalents, marketable securities and restricted cash of $179 million at December 31, 2007. The Company continues to project cash use of less than $100 million in 2008, consistent with prior guidance, and currently projects cash use of less than $50 million in 2009.

The matters set forth in this report are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of CV Therapeutics’ products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property; and other risks detailed from time to time in CV Therapeutics’ SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.